Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Slides were available for p16 assay in 206 of 465 patients, of which 185 were eligible, and p16 and HPV were evaluable in 172 patients. One hundred six (57%) of 185 were p16-positive, and in patients evaluable for both p16 and HPV, 88 (86%) of 102 p16-positive patients were also HPV-positive. Patients who were p16-positive had lower T and higher N categories and better Eastern Cooperative Oncology Group (ECOG) performance status. p16-positive tumors compared with p16-negative tumors were associated with better 2-year overall survival (91% v 74%; hazard ratio [HR], 0.36; 95% CI, 0.17 to 0.74; P = .004) and failure-free survival (87% v 72%; HR, 0.39; 95% CI, 0.20 to 0.74; P = .003). p16 was a significant prognostic factor on multivariable analysis (HR, 0.45; 95% CI, 0.21 to 0.96; P = .04). p16-positive patients had lower rates of locoregional failure and deaths due to other causes. There was a trend favoring the tirapazamine arm for improved locoregional control in p16-negative patients (HR, 0.33; 95% CI, 0.09 to 1.24; P = .13). CONCLUSION:
|
Authors | Danny Rischin, Richard J Young, Richard Fisher, Stephen B Fox, Quynh-Thu Le, Lester J Peters, Ben Solomon, Jimin Choi, Brian O'Sullivan, Lizbeth M Kenny, Grant A McArthur |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 28
Issue 27
Pg. 4142-8
(Sep 20 2010)
ISSN: 1527-7755 [Electronic] United States |
PMID | 20697079
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- Biomarkers, Tumor
- Cyclin-Dependent Kinase Inhibitor p16
- DNA, Viral
- Triazines
- Tirapazamine
- Cisplatin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Australia
- Biomarkers, Tumor
(analysis)
- Carcinoma, Squamous Cell
(chemistry, mortality, pathology, therapy, virology)
- Chemotherapy, Adjuvant
- Cisplatin
(administration & dosage)
- Cyclin-Dependent Kinase Inhibitor p16
(analysis)
- DNA, Viral
(analysis)
- Disease-Free Survival
- Europe
- Female
- Humans
- Immunohistochemistry
- In Situ Hybridization
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(prevention & control)
- Neoplasm Staging
- New Zealand
- North America
- Oropharyngeal Neoplasms
(chemistry, mortality, pathology, therapy, virology)
- Papillomaviridae
(genetics)
- Polymerase Chain Reaction
- Proportional Hazards Models
- Radiotherapy, Adjuvant
- Risk Assessment
- Risk Factors
- South America
- Time Factors
- Tirapazamine
- Treatment Outcome
- Triazines
(administration & dosage)
|